Search results
This narrative review systematically explores the intersection of HIV infection and breast cancer, focusing on the impact of HIV on breast cancer risk, outcomes, and treatment challenges. Keywords: HIV, breast cancer, non-AIDS defining cancers, AIDS, drug–drug interactions
8 maj 2021 · Although the introduction of antiretroviral therapy (ART) has had a significant impact on survival in people living with HIV/AIDS (PLWHA), turning HIV infection into a chronic condition, its relationship with cancer is still the subject of debate.
12 mar 2024 · Despite significant advances in the management of antiretroviral therapy (ART), leading to improved life expectancy for people living with HIV (PLWH), the incidence of non-AIDS-defining cancers, including breast cancer, has emerged as a critical concern.
15 mar 2021 · Studies conducted among PLWH before the widespread use of combined antiretroviral therapy (ART) documented dramatically elevated risks (50-fold to >1000-fold) of certain cancers, Kaposi sarcoma, aggressive non-Hodgkin lymphomas, and cervical cancer, which were later termed AIDS-defining cancers.
Dose-limiting toxic effects and suboptimal receipt of neoadjuvant and adjuvant chemotherapy among patients with breast cancer living with comorbid HIV infection may contribute to this group’s well-documented increased risk of death compared with other women with breast cancer.
7 sty 2022 · Studies of drug–drug interactions and plasma concentrations in people living with HIV are urgently needed to address these questions. HIV might affect access or compliance to cancer treatment in at least two ways.
For now, clinicians should individualize decisions regarding treatment of HIV according to clinical and laboratory findings, cancer treatment plan (chemotherapy, radiotherapy, or surgery), liver or renal disease, potential adverse drug effects (eg, rash, gastrointestinal intolerance, bone marrow suppression), and patient preference.
